The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
Autor Principal: | J. Karalliedde |
---|---|
Formato: | Artigo |
Idioma: | Russian |
Publicado: |
«FIRMA «SILICEA» LLC
2021-04-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Acceso en liña: | https://russjcardiol.elpub.ru/jour/article/view/4323 |
Títulos similares
-
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: John S. Clemmer, et al.
Publicado: (2023-06-01) -
Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
por: Satoru Kuriyama, et al.
Publicado: (2023-10-01) -
Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
por: Massimo Mapelli, et al.
Publicado: (2023-06-01) -
Assessment of Relationship between Galectin-3 and Biochemical Parameters in Peritoneal Dialysis Patients with Left Ventricular Hypertrophy
por: Sultan Alouffi, et al.
Publicado: (2020-08-01) -
Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease
por: Arvin Halim, et al.
Publicado: (2022-03-01)